Combination therapy shown to shrink tumours in many patients whose cancer has spread to the brain
Combination of nivolumab plus ipilimumab can fundamentally change survival expectations.
Bristol-Myers Squibb (BMS) has announced efficacy and safety data from CheckMate -204, the first Phase II study evaluating the cancer immunotherapy combination of nivolumab plus ipilimumab in adult patients with advanced melanoma that has spread to the brain (metastasised).
In this study, 60% of patients treated with combination therapy achieved intracranial (IC) clinical benefit (defined as complete response plus partial response plus stable disease ≥ 6 months). The combination therapy also demonstrated that 21% of patients achieved a complete IC response – meaning there was no detectable sign of the cancer in their brain remaining. Additionally, the data showed that 33% of patients achieved partial responses (significant tumour reduction) and 5% experienced stable disease (no progression in tumour growth). More than 60% of advanced melanoma patients will develop brain metastases, and in these cases, prognosis is poor. These nivolumab plus ipilimumab data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 (abstract #9507).
“The combination of nivolumab plus ipilimumab has completely transformed how we treat and manage advanced melanoma over recent years and has fundamentally changed survival expectations for these patients,” commented Professor John Wagstaff, Professor of Medical Oncology, College of Medicine, Swansea University. “One of the most difficult circumstances in these patients is when the disease progresses to the brain. In these cases, the outlook is generally very poor and treatment limited. These data are therefore really promising and show the potential using immunotherapy can have in wiping out tumours, even in some of the most difficult-to-treat patients.”
In the CheckMate -204 study, the IC objective response rate (ORR) was 55% with a median follow-up of 9.2 months. The safety profile of the study was consistent with previously reported data in melanoma patients without brain metastases, and treatment-related grade 3-4 adverse events (AEs) occurred in 52% of patients with 8% being neurologic in nature, including headaches.
“BMS is very pleased to be sharing these important new data for advanced melanoma patients, whose disease is further complicated by metastasis to the brain,” said Faisal Mehmud, Executive Medical Director, BMS UK & Ireland. “These patients are often excluded from participating in clinical trials and therefore our knowledge of how these therapies work in such cases has historically been limited. These data confirm that the benefits we have seen in advanced melanoma extend to this difficult-to-treat population. We are committed to furthering our understanding of this cancer and ensuring that all people who may benefit from the combination of nivolumab and ipilimumab are able to do so.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance